Global Botanicaland Plant Derived Drugs Market, by Source (Plant, Algae, Macroscopic fungi,and Others), by Dosage Form (Pills, Tablets, Capsules, and Injection), ByTherapeutic Application (Central Nervous System, Cardiovascular Diseases,Infectious Diseases, and Respiratory Diseases), By Region (North America,Europe, Latin America, Middle East, Asia Pacific, and Africa) is estimated tobe valued at US$ 30.1 billion in 2017 and is projected to exhibit a CAGR of6.3% over the forecast period (2017 - 2025).
High risk of side-effects due toconsumption of synthetic drugs such as allergic reaction and gastrointestinalupsets, drug recalls, and high cost of specialty drugs are propelling demandfor botanical and plant derived drugs. Furthermore, legalization of medicinalcannabis in several countries have made the manufacturers to invest in theresearch and development to derive drugs for cannabis. For instance, one of thedrug by GW Pharmaceuticals, Epidiolex drug consists of cannabidivarin (CBDV) isin developmental process, which will be used in clinical trials for treatmentresistant epilepsy, supported by NSW and Queensland government in 2016.Moreover, Insys Therapeutics, an America-based company have Subsys drug intheir product portfolio, which is prescribed for the treatment of advanced painassociated with cancer. The subsys is a synthetic version of cannabidiol (CBD)and has accounted for almost 100% of the company’s 2014 year-to-date revenue.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1737
Browse 35 Market Data Tables and41 Figures spread through 179 Pages and in-depth TOC on "Botanical andPlant Derived Drugs Market, by Source (Plant, Algae, Macroscopic fungi, andOthers), by Dosage Form (Pills, Tablets, Capsules, and Injection), byTherapeutic Application (Central Nervous System, Cardiovascular Diseases,Infectious Diseases, and Respiratory Diseases), by Region (North America,Europe, Latin America, Middle East, Asia Pacific, Africa) - Global Forecast to2026"
Increasing applications ofbotanical and plant derived drugs are receiving regulatory approvals withrespect to cancer patients - as a cure and as a supplement to currenttreatments, which provides a great opportunity for conducting clinical trials.For instance, in June 2017, Medlab Clinical received approval to begin humantrials of two different cannabis based medicines – NanaBis and NanaBidial.NanaBis is packaged as a mouth spray and will be clinically tested in advancedstage for cancer patients with intractable pain. NanaBidial comprisescannabidiol derived from marijuana and is indicated for chemotherapy inducednausea and vomiting, with a secondary endpoint in patients suffering seizures
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/botanical-and-plant-derived-drugs-market-1737
Key takeaways of the Botanicaland Plant Derived Drugs Market:
The global botanical and plantderived drugs market is expected to expand at a CAGR of 6.3% during theforecast period (2018 – 2026), owing to increasing adoption of herbal drugsover the synthetic drugs.
Among source type, plant segmentis expected to hold a major market share over the forecast period, owing toincreasing number of clinical trials for medicinal cannabis.
Furthermore, Asia Pacific isexpected to show the most lucrative CAGR in the botanical and plant deriveddrugs market, owing to entry of local players and key players, which areengaged in development of herbal medicines.
Some of the major playersoperating in global botanical and plant derived drugs market include BayerHealthcare, GlaxoSmithKline, Pfizer, Inc. Sanofi, Actelion Pharmaceuticals,Aimil Pharmaceuticals, Allergan, AstraZeneca, Boehringer Ingelheim, and GWPharmaceuticals.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1737
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
